RedHill Biopharma Ltd. Reports Positive PK Clinical Studies Towards Planned NDA with RHB-102 (Anti-Emetic)
Published: Oct 08, 2013
TEL-AVIV, Israel, Oct. 8, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, today reported positive results from two supplementary pharmacokinetic (PK) studies with RHB-102, an anti-emetic oncology-support drug.
Help employers find you! Check out all the jobs and post your resume.